Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC

• Published in: Molecular cancer research Vol. 15; no. 3; pp. 304 - 316
• Main Authors: Güttlein, Leandro N., Benedetti, Lorena G., Fresno, Cristóbal, Spallanzani, Raúl G., Mansilla, Sabrina F., Rotondaro, Cecilia, Raffo Iraolagoitia, Ximena L., Salvatierra, Edgardo, Bravo, Alicia I., Fernández, Elmer A., Gottifredi, Vanesa, Zwirner, Norberto W., Llera, Andrea S., Podhajcer, Osvaldo L.
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research Inc 01.03.2017
• Subjects: Animal models; Animals; Breast cancer; Breast Neoplasms - enzymology; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer; Cell cycle; Cell Growth Processes - physiology; Cell Line, Tumor; Colonization; Cyclooxygenase-2; ErbB-2 protein; Female; Gene expression; Glycoproteins; Humans; Implantation; Lungs; Mammary Neoplasms, Experimental - enzymology; Mammary Neoplasms, Experimental - genetics; Mammary Neoplasms, Experimental - metabolism; Mammary Neoplasms, Experimental - pathology; MCF-7 Cells; Metastases; Metastasis; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Osteonectin; Osteonectin - genetics; Osteonectin - metabolism; Prognosis; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Signatures; Stroma; Suppressor cells; Treatment Outcome

Understanding the mechanism of metastatic dissemination is crucial for the rational design of novel therapeutics. The secreted protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein which has been extensively associated with human breast cancer aggressiveness although the underl...